financetom
Business
financetom
/
Business
/
GIC Re net profit rises 6.1% to Rs 732 crore in Q1
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GIC Re net profit rises 6.1% to Rs 732 crore in Q1
Aug 10, 2023 2:22 PM

GIC Re on Thursday reported a 6.1 percent increase in net profit at Rs 732 crore in the June quarter, despite a steep fall in gross premium income and massive underwriting of losses.

The company — the country’s only reinsurer — had recorded a net profit of Rs 689.72 crore in the year-ago period, it said.

GIC Re said its gross premium income in the first quarter of the current fiscal declined to Rs 8,917.71 crore from Rs 11,021.83 crore a year ago.

It underwrote Rs 1,557.44 crore losses in the quarter under review compared to that of Rs 776.29 crore in the year-ago period.

The mounting underwriting of losses saw the combined ratio — a key profitability metric in general insurance — falling to 118.47 during the quarter as against 110.97 for the year-ago period.

The adjusted combined ratio — the sum of the loss ratio and the expense ratio — stood at 97.24 as against 97.01 in the year-ago quarter.

The solvency ratio of the state-run firm rose to 2.88 from 2.14.

Total assets of GIC Re rose to Rs 1,64,258.75 crore from Rs 1,46,178.09 crore.

The reinsurer’s gross premium income during the quarter declined to Rs 8,917.71 crore from Rs 11,021.83 crore, while the net premium fell to Rs 8,231.17 crore from Rs 10,493.68 crore.

The company paid Rs 1,840.94 crore in commission as against Rs 1,655.56 crore in the June quarter last year. The commission as a percentage of net premium increased to 22.4 percent from 15.8 percent a year earlier.

The firm’s management expenses nearly doubled to Rs 86.28 crore from Rs 49.80 core.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor
VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor
Dec 23, 2024
09:17 AM EST, 12/23/2024 (MT Newswires) -- VYNE Therapeutics ( VYNE ) shares were edging higher Monday morning after the biopharmaceutical company reported positive phase 1a results for its novel BD2-selective BET inhibitor VYN202. The company said the results support the inhibitor's potential as a new oral treatment for various immune-mediated disorders. VYN202 showed a favorable safety and tolerability profile...
Polish e-commerce Allegro's unit sues Alphabet for $568 million
Polish e-commerce Allegro's unit sues Alphabet for $568 million
Dec 23, 2024
GDANSK (Reuters) - A subsidiary of Polish e-commerce platform Allegro on Monday filed a lawsuit against Google-owner Alphabet, Google Ireland, and Google LLC, seeking 2.33 billion zlotys ($568 million) in damages, citing allegations of anti-competitive practices, Allegro said in a statement. The unit, Ceneo, is demanding compensation for losses it says it has suffered due to Google's practices of preferring...
Polish e-commerce Allegro's unit sues Alphabet for $568 million
Polish e-commerce Allegro's unit sues Alphabet for $568 million
Dec 23, 2024
GDANSK, Dec 23 (Reuters) - A subsidiary of Polish e-commerce platform Allegro on Monday filed a lawsuit against Google-owner Alphabet, Google Ireland, and Google LLC, seeking 2.33 billion zlotys ($568 million) in damages, citing allegations of anti-competitive practices, Allegro said in a statement. The unit, Ceneo, is demanding compensation for losses it says it has suffered due to Google's practices...
Wave Life Sciences Files Clinical Trial Application for WVE-007 To Treat Obesity
Wave Life Sciences Files Clinical Trial Application for WVE-007 To Treat Obesity
Dec 23, 2024
09:16 AM EST, 12/23/2024 (MT Newswires) -- Wave Life Sciences ( WVE ) said Monday it has filed its first clinical trial application for WVE-007 to treat obesity. The company said it expects approval of the clinical trial application and the start of the first-in-human trial of WVE-007 in Q1 2025. WVE-007 is a new approach to treat obesity that...
Copyright 2023-2026 - www.financetom.com All Rights Reserved